Evidence map›Paper›PMID 38349577›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2024

Improvement of thrombosis management in patients with cancer: a practical consensus document of recommendations for cancer-associated thrombosis patients' healthcare in Spain.

Andrés Muñoz Martín, Antonio Javier Trujillo-Santos, Edelmira Martí, Luis Jara-Palomares, Raquel Macías Montero, Enrique Gallardo, Juan José López-Núñez, Elena Brozos-Vázquez, Verónica Robles-Marinas, Pedro Pérez-Segura and 1 more

Abstract readConsensus Statement
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Andrés Muñoz MartínOncology Department, Hospital General Universitario Gregorio Marañón, Universidad Complutense Madrid, Madrid, Spain. andresmunmar@hotmail.com.ORCID http://orcid.org/0000-0001-6977-8249
Antonio Javier Trujillo-SantosInternal Medicine Department, Hospital General Universitario Santa Lucía, Cartagena, Murcia, Spain.
Edelmira MartíHaematology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.ORCID http://orcid.org/0000-0002-5678-2916
Luis Jara-PalomaresPneumology Department, Hospital Universitario Virgen del Rocío, Seville, Spain.
Raquel Macías MonteroOncology Department, Hospital de Badajoz, Badajoz, Spain.
Enrique GallardoOncology Department, Parc Taulí Hospital Universitari, Barcelona, Spain.ORCID http://orcid.org/0000-0002-1375-3488
Juan José López-NúñezInternal Medicine Department, Hospital Germans Trias i Pujol, Barcelona, Spain.ORCID http://orcid.org/0000-0002-1226-2353
Elena Brozos-VázquezOncology Department, Hospital Clínico Universitario de Santiago, A Coruña, Spain.
Verónica Robles-MarinasHematology Department, Hospital Universitario de Cabueñes, Gijón, Spain.
Pedro Pérez-SeguraOncology Department, Hospital Clínico Universitario San Carlos, Madrid, Spain.
Pedro Ruíz-ArtachoCIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer patients are at risk of venous thromboembolism (VTE), its recurrence, but also at risk of bleeding while anticoagulated. In addition, cancer therapies have been associated to increased VTE risk. Guidelines for VTE treatment in cancer patients recommend low molecular weight heparins (LMWH) or direct oral anticoagulants (DOAC) for the initial treatment, DOAC for VTE short-term treatment, and LMWH or DOAC for VTE long-term treatment. This consensus article arises from a collaboration between different Spanish experts on cancer-associated thrombosis. It aims to reach an agreement on a practical document of recommendations for action allowing the healthcare homogenization of cancer-associated thrombosis (CAT) patients in Spain considering not only what is known about VTE management in cancer patients but also what is done in Spanish hospitals in the clinical practice. The text summarizes the current knowledge and available evidence on the subject in Spain and provides a series of practical recommendations for CAT management and treatment algorithms to help clinicians to manage CAT over time.

Indexed as

AnticoagulantsNeoplasmsThrombosisVenous ThromboembolismHeparin, Low-Molecular-WeightHumansPractice Guidelines as TopicSpainAnticoagulantsHeparin, Low-Molecular-WeightCancer-associated thrombosisPractical consensusSpainThrombosis management

Identifiers

PMID38349577
PMCPMC11108917

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.